FDA Okays Empagliflozin for HFrEF FDA Okays Empagliflozin for HFrEF
The drug is approved as a treatment for adults with heart failure with reduced ejection fraction (HFrEF) regardless of whether patients have diabetes.FDA Approvals
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Alert Source Type: news
More News: Cardiology | Diabetes | Empagliflozin | Endocrinology | Heart | Heart Failure | Jardiance